Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract

Yu, Yang; Zhu, Shengtao; Li, Peng; Min, Li; Zhang, Shutian

doi:10.1038/s41419-018-0982-2

Cited by 76 publications

(80 citation statements)

References 114 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, recent studies have elucidated the protective role of H. pylori in an inflamed gut by inducing the expression of Foxp3+ Tregs and suppressing inflammatory cytokines [57]. However, the trade-off between a protective effect in IBD and risk in gastric disease by H. pylori infection is not completely understood [58]. In this study, the supernatants of tested L. rhamnosus strains inhibited the viability of the tested pathogenic indicators (Table 1).…”

Section: Discussionmentioning

confidence: 62%

Anti-Inflammatory and Gut Microbiota Modulatory Effect of Lactobacillus rhamnosus Strain LDTM 7511 in a Dextran Sulfate Sodium-Induced Colitis Murine Model

et al. 2020

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a group of conditions involving chronic relapsing-remitting inflammation of the gastrointestinal tract with an unknown etiology. Although the cause–effect relationship between gut microbiota and IBD has not been clearly established, emerging evidence from experimental models supports the idea that gut microbes play a fundamental role in the pathogenesis of IBD. As microbiome-based therapeutics for IBD, the beneficial effects of probiotics have been found in animal colitis models and IBD patients. In this study, based on the dextran sulfate sodium (DSS)-induced colitis mouse model, we investigated Lactobacillus rhamnosus strain LDTM 7511 originating from Korean infant feces as a putative probiotic strain for IBD. The strain LDTM 7511 not only alleviated the release of inflammatory mediators, but also induced the transition of gut microbiota from dysbiotic conditions, exhibiting the opposite pattern in the abundance of DSS colitis-associated bacterial taxa to the DSS group. Our findings suggest that the strain LDTM 7511 has the potential to be used as a probiotic treatment for IBD patients in comparison to L. rhamnosus GG (ATCC 53103), which has been frequently used for IBD studies.

show abstract

Section: Discussionmentioning

confidence: 62%

Anti-Inflammatory and Gut Microbiota Modulatory Effect of Lactobacillus rhamnosus Strain LDTM 7511 in a Dextran Sulfate Sodium-Induced Colitis Murine Model

et al. 2020

View full text Add to dashboard Cite

show abstract

“…45 Indeed, preclinical studies provide evidence that non-pylori enterohepatic Helicobacter species can enhance an IBDlike bowel inflammation. 46 An association between the presence of H pylori in the intestinal mucosa, identified by 16S rRNA gene sequencing, and a UC-like pattern of patients with CD was observed. 47 A pilot study reported that 40% and 56.6% of the histologic samples from the colon of newly diagnosed patients with UC were positive for H pylori by Giemsa and immunohistochemistry staining, respectively.…”

Section: Infl Ammatory Bowel D Is E a S Ementioning

confidence: 90%

“…6 A systematic review evaluated the relationship between H pylori infection and obesity among Chinese adults. The prevalence of H pylori was 42% (95% CI, [37][38][39][40][41][42][43][44][45][46][47] and mean difference of BMI between subjects with and without H pylori infection was 0.94 (95% CI, −0.04 to 1.91). The OR value was 1.20 (95% CI, 1.13-1.…”

Section: Metabolic Syndrome and Obesitymentioning

confidence: 99%

See 1 more Smart Citation

Review: Extragastric diseases andHelicobacter pylori

et al. 2020

View full text Add to dashboard Cite

The involvement of Helicobacter pylori infection in many extra‐gastroduodenal manifestations remains a fascinating field of investigation. However, for several of these supposed associations, the potential pathogenic mechanism remains unclear. The present review highlights the main associations of H pylori with extra‐gastroduodenal manifestations reported during the last year. We searched for the most relevant studies on this topic, published between April 2019 and March 2020, identified using the term “Helicobacter” in the MEDLINE/Pubmed database. Consistent data emerged from studies investigating metabolic syndrome and ischaemic cardiovascular diseases. Other reported fields of investigation were hepatology, especially focused on non‐alcoholic steatohepatitis, neurology, including Parkinson’s disease and Alzheimer’s disease, as well as dermatology. Inflammatory bowel disease (IBD), that comprises Crohn’s disease and ulcerative colitis, may originate from a dysregulation of the host’s immune response to commensal bacteria in individuals with genetic predisposition. The reduction of biodiversity and other specific imbalances in the faecal microbiome composition of IBD patients compared to that of healthy controls support this hypothesis. In this context, an inverse correlation between H pylori infection and IBD prevalence has been confirmed. Similar results were found in patients with kidney diseases and allergic manifestations. There are indications of the possible involvement of H pylori infection in metabolic syndrome and ischaemic cardiovascular diseases. However, due to a series of factors linked to study designs and the multifactorial pathogenesis of some diseases, further studies are needed.

show abstract

“…Both Desulfovibrio and Bilophila are conditional pathogens, creating H 2 S in combination with H 2 by sulfuric acid or sulfur-containing compounds, which has an important relationship with the in ammatory state of the intestinal epithelium (such as UC) [42]. Studies have shown that the body with Helicobacter removed is more susceptible to colitis than the untreated group, suggesting that Helicobacter has potential protective effects on colitis patients [43]. Therefore, these result further indicated that the amelioration of UC using SLBZS may be mediated by the enrichment of bene cial bacteria to product SCFA for protection of colon mucosa and a reduction in bacteria, such as Bacteroides, Desulfovibrio and Bilophila, to inhibit in ammation.…”

Section: Discussionmentioning

confidence: 99%

ShenLing BaiZhu San alleviates Ulcerative Colitis in Rats by Regulating Gut Microbiota

Gu¹,

Zhou²,

Yao³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Recent studies have suggested that Shenling Baizhu San (SLBZS), an complementary and alternative medical therapy for ulcerative colitis (UC), alleviate clinic symptoms by the improvement of biochemical criteria and restoration of the intestinal barrier function. SLBZS as a famous Chinese herbal formula has been reportedly used to treat UC, of which mechanism is unknown. This study investigated the therapeutic effects of SLBZS on restoring the gut microbiota in a UC rat model. Methods: We proposed a 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced UC rat model to monitor the structural modulation of the gut microbiota. The test period was 10 days (observation for two days after modeling, treatment for 8 days by SLBZS). In this study, the level of inflammatory cytokines and activity of antioxidant enzymes in serum were ascertained by enzyme-linked immunosorbent assay (ELISA) and histological changes of colon were observed. Feces were collected for high-throughput sequencing of 16S rRNA gene. Results: SLBZS partly reduced the diversity of the gut microbiota, while the abundance of that is increased. Furthermore, at the genus level, the relative abundance of short chain fatty acids (SCFA) producing bacteria including Prevotella and Oscillospira increased, while the relative abundance of harmful bacteria including Desulfovibrio, and Bilophila decreased. Additionally, SLBZS could improve the lesions of colon and significantly reduce the expression of Interleukin-6 (IL-6) and Myeloperoxidase (MPO) and increase the activities of Superoxide dismutase (SOD) and Catalase (CAT) in rats serum. Conclusions: These results demonstrate that SLBZS may treat UC effectively by inhibiting inflammation, enhancing antioxidant capacity and regulating gut microbiota.

show abstract

Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract

Cited by 76 publications

References 114 publications

Anti-Inflammatory and Gut Microbiota Modulatory Effect of Lactobacillus rhamnosus Strain LDTM 7511 in a Dextran Sulfate Sodium-Induced Colitis Murine Model

Anti-Inflammatory and Gut Microbiota Modulatory Effect of Lactobacillus rhamnosus Strain LDTM 7511 in a Dextran Sulfate Sodium-Induced Colitis Murine Model

Review: Extragastric diseases andHelicobacter pylori

ShenLing BaiZhu San alleviates Ulcerative Colitis in Rats by Regulating Gut Microbiota

Contact Info

Product

Resources

About